¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"organic reaction type"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • delayed allergic reaction
    Áö¿¬¾Ë·¹¸£±â¹ÝÀÀ
  • delayed cell-mediated reaction
    Áö¿¬¼¼Æ÷¸Å°³¹ÝÀÀ
  • delayed hemolytic transfusion reaction
    Áö¿¬¿ëÇ÷¼º¼öÇ÷¹ÝÀÀ
  • delayed reaction
    Áö¿¬¹ÝÀÀ
  • depressive reaction
    ¿ì¿ï¹ÝÀÀ
  • dissociative reaction
    ÇØ¸®¹ÝÀÀ
  • donor reaction
    Á¦°øÀÚ¹ÝÀÀ, °ø¿©ÀÚ¹ÝÀÀ
  • dopa reaction
    µµÆÄ¹ÝÀÀ
  • downgrading reaction
    ÇÏÇâ¹ÝÀÀ
  • exergonic reaction
    ¿¡³ÊÁö¹æÃâ¹ÝÀÀ
  • exoergic reaction
    ¿¡³ÊÁö¹æÃâ¹ÝÀÀ
  • exothermic reaction
    ¹ß¿­¹ÝÀÀ
  • explosive reaction
    Æø¹ßÀû¹ÝÀÀ
  • endergonic reaction
    1. ¿¡³ÊÁöÁõ°­¹ÝÀÀ 2. ¿¡³ÊÁöÈí¼ö¹ÝÀÀ
  • endothermic reaction
    Èí¿­¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • cell-mediated reaction
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • cessation reaction
    Á¤Áö¹ÝÀÀ
  • chain reaction
    ¿¬¼â¹ÝÀÀ
  • chain initiation reaction
    ¿¬¼â°³½Ã¹ÝÀÀ
  • cholera red reaction
    ÄÝ·¹¶óÀû»ö¹ÝÀÀ
  • circular reaction
    ¼øÈ¯¹ÝÀÀ
  • color reaction
    ¹ß»ö¹ÝÀÀ, »öä¹ÝÀÀ
  • common reaction
    Á¤»ó¹ÝÀÀ
  • complement fixation reaction
    º¸Ã¼°áÇÕ¹ÝÀÀ, µµ¿òü°áÇÕ¹ÝÀÀ
  • conglutination reaction
    ±³Âø¹ÝÀÀ
  • conjunctival reaction
    °á¸·¹ÝÀÀ
  • consensual pupillary reaction
    °ø°¨µ¿°ø¹ÝÀÀ
  • conversion reaction
    Àüȯ¹ÝÀÀ
  • counter reaction
    ¿ª¹ÝÀÀ
  • coupled reaction
    °ø¿ª¹ÝÀÀ, ¦Áø¹ÝÀÀ, ¿¬°á¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • fuchsinophil reaction
    Ç«½Åģȭ¼º ¹ÝÀÀ(¡­Úãëë).
  • gel diffusion precipitin reaction
    ÇÑõȮ»ê ħ°­¹ÝÀÀ
  • general reaction
    Àü½Å¹ÝÀÀ.
  • gluteal reaction
    µÐ ¹ÝÀÀ(ÔëÚãëì).
  • gold reaction
    ±Ý¹ÝÀÀ.
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ(ì¹ãÕø¸ÓßâÖñ«Úãëë).
  • graft versus host reaction (GVHR)
    ´ë¼÷ÁÖÀÌ½ÄÆí¹ÝÀÀ
  • grief reaction
    ¾Öµµ<ºñ¾Ö>¹ÝÀÀ(äîÓú<Ýèäî>Úãëë)
  • gross stress reaction
    ´ëÀÚ±Ø<ÃÑüÀû½ºÆ®·¹½º>¹ÝÀÀ(ÓÞí©Ð½<õÅô÷îÜ~>Úãëë)
  • group reaction
    Áý´Ü¹ÝÀÀ(̤ËÀËÑËô).
  • heat of reaction
    ¹ÝÀÀ¿­(Úãëëæð).
  • hemagglutination inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ.
  • hemoclastic reaction
    Ç÷±¸ºØ±«¹ÝÀÀ.
  • hemolytic transfusion reaction
    ¿ëÇ÷¼º ¼öÇ÷¹ÝÀÀ.
  • heterogeneous reaction
    ºÒ±ÕÀϹÝÀÀ, ºÒ±ÕÁú¹ÝÀÀ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • golgi type ii neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷
  • growth onset type diabetes
    Ãʱâ´ç´¢º´.
  • hebephrenic type
    ÆÄ°úÇü(÷òÍþúþ)
  • hemangioma,granulation tissue type
    À°¾ÆÁ¶Á÷Çü
  • hemochorial type
    À¶Ç÷¸ðÇü(ëÖúìÙ¾úþ).
  • hemoglobin C type
    CÇü Ç÷»ö¼Ò
  • hemoglobin E type
    E Çü Ç÷»ö¼Ò
  • hepatitis,type a
    A Çü
  • hepatitis,type b
    B Çü
  • herpes simplex virus type 1
    Á¦1Çü ´Ü¼øÆ÷Áø¹ÙÀÌ·¯½º
  • herpes simplex virus type 2
    Á¦2Çü ´Ü¼øÆ÷Áø¹ÙÀÌ·¯½º
  • htlv,type i
    type 1Çü
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • Sakaguchi reaction
    »çÄ«±¸Âî ¹ÝÀÀ(Úãëë)
  • Salkowski reaction
    »ìÄÚÇÁ½ºÅ° ¹ÝÀÀ(Úãëë)
  • Sanger reaction
    »ý°Å ¹ÝÀÀ(Úãëë)
  • scalar reaction
    ½ºÄ®¶ó ¹ÝÀÀ(Úãëë)
  • Schardinger reaction
    »þ¸£µù°Å ¹ÝÀÀ(Úãëë)
  • second-order reaction
    ÀÌÂ÷ ¹ÝÀÀ(ì£ó­Úãëë)
  • sequential reaction
    ¼øÂ÷¹ÝÀÀ(â÷ó­Úãëë)
  • Swartzman reaction
    ½´¹Ù¸£Â길 ¹ÝÀÀ(Úãëë)
  • side reaction
    ºÎÀÛ¿ë(ÜùíÂéÄ)
  • specific reaction rate
    ƯÀÌ ¹ÝÀÀ¼Óµµ(÷åì¶ÚãëëáÜÓø)
  • spontaneous reaction
    "Àڹ߹ÝÀÀ(í»Û¡Úãëë), ÀúÀý·Î ¹ÝÀÀ(Úãëë)"
  • spreading reaction
    ÆÛÁü ¹ÝÀÀ(Úãëë)
  • staircase reaction
    °è´Ü ¹ÝÀÀ(Í­Ó«Úãëë)
  • standard reaction conditions
    Ç¥ÁØ ¹ÝÀÀÁ¶°Ç(øöñÞÚãëëðÉËì)
  • stereoselective reaction
    ÀÔü¼±Åà ¹ÝÀÀ(Ø¡ô÷àÔ÷ÉÚãëë)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
TOC total organic carbon
TODS toxic organic dust syndrome
VOC volatile organic chemical
AFB Acid-Fast Bacillus(Type that causes Tuberculosis)
DMD Duchenne type Muscular Dystrophy; ¾Ç¼ºÇü DuchenneÇü ±ÙÀÌ¿µ¾çÁõ
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
GRF Ground Reaction Forces
ISPCR i situ polymerase chain reaction
IPCR Inverse polymerase chain reaction
LAR Late asthmatic reaction
LCR late cutaneous reaction
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cutaneous reaction
    ÇǺΠ¹ÝÀÀ
  • Dakin-West`s reaction
    µ¥ÀÌŲ-¿þ½ºÆ® ¹ÝÀÀ
  • Dakin`s reaction
    µ¥ÀÌŲ ¹ÝÀÀ
  • delayed reaction
    Áö¿¬ ¹ÝÀÀ
  • depressive reaction
    ¿ì¿ï ¹ÝÀÀ
  • desmoid reaction
    Àδë¾ç ¹ÝÀÀ
  • donor reaction
    °øÇ÷ÀÚ ¹ÝÀÀ
  • emergency reaction
    ±ä±Þ ¹ÝÀÀ
  • endothermic reaction
    Èí¿­ ¹ÝÀÀ
  • eosinophilic leukemoid reaction
    È£»ê±¸¼º ¹éÇ÷º´¾ç ¹ÝÀÀ
  • erythema wheal reaction
    È«¹Ý ±¸Áø ¹ÝÀÀ
    ¾Ë·¹¸£±â¿øÀÇ °¨ÀÛ »óŸ¦ °Ë»öÇÒ ¸ñÀûÀ¸·Î ¾Ë·¹¸£±â¿ø ÃßÃâ¹°À» ÇǺΠǥ¸é¿¡ ÇÑ ¹æ¿ï ¶³¾î¶ß¸®°í ±× ¾×À» ÅëÇØ¼­ ÇǺΠǥ¸éÀ» ¹Ù´Ã·Î ±ÜÀ¸¸é À¯¸®µÇ´Â È­ÇÐ Àü´Þ ¹°Áú ¶§¹®¿¡ ÆØÁø ¹× È«¹ÝÀÌ ÃâÇöÇÑ´Ù. ¾Ë·¹¸£±â¿ø °Ë»çÀÎ °æ¿ì´Â ÆØÁø°æ ¶Ç´Â È«¹Ý°æÀÌ ´ëÁ¶ÀÇ 2¹è ÀÌ»ó, ȤÀº ±¸ÁøÀÇ Á÷°æÀÌ 5mm ÀÌ»óÀ» ¾ç¼ºÀ¸·Î ÇÑ´Ù.
  • escape reaction
    µµÇÇ ¹ÝÀÀ
  • eutectic reaction
    °øÁ¤ ¹ÝÀÀ
    ÇÕ±ÝÀ» ¿ëÀ¶ »óÅ¿¡¼­ ³Ã°¢ÇÒ ¶§ ÇϳªÀÇ ¾×»ó¿¡¼­ µÎ °³ÀÇ °í»óÀÌ µ¿½Ã¿¡ Çü¼ºµÇ´Â ¹ÝÀÀ.
  • exergonic reaction
    ¹ß¿­ ¹ÝÀÀ, ¿¡³ÊÁö ¹ß»ý ¹ÝÀÀ, ¿¡³ÊÁö ¹æÃâ ¹ÝÀÀ
  • exothermal reaction
    ¹ß¿­ ¹ÝÀÀ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
deoxyribonucleases, type II site-specific <enzyme> Enzyme systems containing a single subunit and requiring only magnesium for endonucleolytic activity. The corresponding modification methylases are separate enzymes. The systems recognise specific short DNA sequences and cleave either within, or at a short specific distance from, the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.4
(12 Dec 1998)
deoxyribonucleases, type I site-specific <enzyme> Enzyme systems containing three different subunits and requiring ATP, s-adenosylmethionine, and magnesium for endonucleolytic activity to give random double-stranded fragments with terminal 5'-phosphates. They function also as DNA-dependent atpases and modification methylases, catalyzing the reactions of EC 2.1.1.72 and EC 2.1.1.73 with similar site-specificity. The systems recognise specific short DNA sequences and cleave at sites remote from the recognition sequence. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.3
(12 Dec 1998)
diabetes, type 1 Insulin dependent diabetes or juvenile diabetes.
(12 Dec 1998)
diabetes, type 2 Non-insulin dependent diabetes, adult-onset diabetes or insulin-resistant diabetes.
(12 Dec 1998)
disease, gaucher's type 1 A progressive genetic disease caused by a defect in an enzyme. The enzyme, called glucocerebrosidase, is needed to break down the chemical glucocerebroside. The enzyme defect in persons with Gaucher's disease (GD) leads to the accumulation of glucocerebroside in the spleen, liver, and lymph nodes. The most common early sign is enlargement of the spleen (located in the upper left abdomen). Other signs include low red blood cell counts (anaemia), a decrease in blood clotting cells (platelets), increased pigmentation of the skin, and a yellow fatty spot on the white of the eye (a pinguecula). Severe bone involvement can lead to pain and collapse of the bone of the hips, shoulders, and spine. The GD gene is on chromosome 1. The disease is a recessive trait. Both parents carry a GD gene and transmit it for their child with the disease. The parents' risk of a child with the disease is 1 in 4 with each pregnancy. This type of Gaucher's disease (noncerebral juvenile Gaucher's disease) is most common in Ashkenazi Jews (of European origin) and is the most common genetic disease among Jews in the United States.
(12 Dec 1998)
immunization, haemophilus influenzae type b See immunization, hib.
(12 Dec 1998)
influenza type a A common acute viral infection of the nasopharynx and respiratory tract which occurs in epidemic forms. A common cause is the Influenza a virus. Annual vaccination is recommended for those in high risk groups (health care workers, elderly and immunocompromised) for influenza infection.
Common symptoms include runny nose, fever, weakness, headache, body aches, muscle aches, nausea and back pain. Treatment of symptoms has been successful with amantadine or rimantadine.
(27 Sep 1997)
interferon type I <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta).
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
interferon type II <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced)
(12 Dec 1998)
ocean-type fish An anadromous fish that shows no indication on its scales or other hard parts of an extended freshwater residence early in its life.
(09 Oct 1997)
Ellis type 1 glomerulonephritis An obsolete designation for glomerulonephritis presenting as acute glomerulonephritis, followed by complete recovery in most cases, or the development of rapidly progressive glomerulonephritis, or incomplete remission with persistent proteinuria and subsequent development of chronic glomerulonephritis.
Synonym: Ellis type 1 nephritis.
(05 Mar 2000)
Ellis type 1 nephritis An obsolete designation for glomerulonephritis presenting as acute glomerulonephritis, followed by complete recovery in most cases, or the development of rapidly progressive glomerulonephritis, or incomplete remission with persistent proteinuria and subsequent development of chronic glomerulonephritis.
Synonym: Ellis type 1 nephritis.
(05 Mar 2000)
Ellis type 2 glomerulonephritis An obsolete designation for glomerulonephritis which is usually not related to preceding bacterial infection; characterised by an insidious onset of the nephrotic syndrome, failure of complete remission, and eventual development of chronic renal failure. The kidneys usually show membranous glomerulonephritis.
Synonym: Ellis type 2 nephritis.
(05 Mar 2000)
Ellis type 2 nephritis An obsolete designation for glomerulonephritis which is usually not related to preceding bacterial infection; characterised by an insidious onset of the nephrotic syndrome, failure of complete remission, and eventual development of chronic renal failure. The kidneys usually show membranous glomerulonephritis.
Synonym: Ellis type 2 nephritis.
(05 Mar 2000)
Ellis type II <nephrology> A type of nephritis that is characterised by low serum albumin, large amount of protein in the urine and swelling (oedema). Swelling, weight gain, high blood pressure and anorexia are key features. Nephrotic syndrome can be seen with a number of illness that cause damage to the kidney glomerulus.
Examples include diabetes, hereditary disorders, lupus, multiple myeloma, amyloidosis, glomerulonephritis, minimal change disease and membranous glomerulonephritis.
(27 Sep 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
ÅëÇÕ°Ë»ö ¿Ï·á